Next Phase Newsletter

A single family office based in the USA actively invests in pre-seed and seed-stage companies, and occasionally invests in Series A rounds as well. The firm is open to global companies, including those in emerging countries.

The firm is most interested in therapeutics opportunities and in terms of indication, the firm is most interested in oncology and CNS. The firm is open to various modalities but has mostly looked at small molecule and some peptide drugs. In addition, the firm is also interested in repurposed assets that have initially been shelved by big pharma. In terms of stage of development, the firm will look at pre-clinical and early clinical opportunities. The firm is also interested in diagnostics and some digital health. Their interests in healthtech include technologies that help health systems reduce costs, B2C products in mental health (especially pediatric) and chronic disease, and more.

The firm does not have specific company or management team requirements. The firm prefers to co-invest alongside likeminded investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Europe with offices throughout USA and Europe is investing out of its first fund and makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs. The firm invests globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm is based in Europe and focuses on early to growth and expansion stage including spin-offs and restarts. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity/venture capital company founded in 2001 and headquartered in the USA makes growth equity investments ranging from approximately $10 to $40 million over the investment’s lifetime. The firm primarily invests within the United States but is open to consider international investment as well.

The firm is currently looking for commercial stage companies in areas of medical technology and devices, life science instruments and tools, healthcare IT, healthcare services, agriculture and animal health.

The firm only invests in companies with commercial revenue. The firm supports organic growth strategies, which allow for gross profit growth and investment in product pipelines and commercial expansion. The firm looks to take a seat on the company board and prefers to be the lead or sole institutional investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage fund focused on angel investment and incubation in the healthcare field is currently investing from a fund backed by six major Chinese companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm is seeking to make investments in companies with an intersection of AI in various verticals such as manufacturing, automotive, healthcare and sustainability. The firm also makes investments in core technology enablers of AI. The firm has $300M AUM. Check size ranges from $1-10M but typically falls in the $3-5M range and the firm prefers equity investments. The firm has made three investments in companies with applications of AI in healthcare. The firm typically invest in Series A and B but will look at Pre Series A companies that are getting close to the Series A round. The firm is open to global opportunities.

The firm seeks to make investments relating to AI. The firm will look at therapeutics, medical devices, digital health and diagnostics as long as it is AI enabled. The firm is agnostic to subsector and indication. The firm does not look at pre-clinical and pre-prototype companies, but will look at earlier companies that are preparing for clinical trials on a case by case basis. The firm will invest in all three classes of medical devices.

The firm looks for management teams with a good network, and a diverse founding team is of particular interest. In healthcare investments, the firm typically co-invests, and will seek a board observer seat.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA, Canada, and Europe, is investing from its latest fund which closed in early 2021. The firm makes seed, early-stage, and growth equity investments in biotechnology and medical devices companies, and with the latest fund they seek to invest in 20 or more biotech startups. The firm’s typical investment size for early-stage companies is between $5M to $15M. The firm can allocate up to $20M total over the life of the investment.  The firm focuses on companies that are based in the US, Canada, and Western Europe, but also selectively invests in companies in Asia. The firm is actively seeking new investment opportunities.

The firm is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address immuno-oncology, orphan/rare or genetic-based diseases, inflammation, infectious diseases and specific viruses, microbiome, and fibrosis and CNS indications. The firm is also interested in regenerative medicine and gene therapy. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. The firm prefers devices with proof-of-concept and strong IP.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.
 
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.